共 50 条
- [21] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyLANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142Reid, TonyOronsky, BryanScicinski, JanScribner, Curt L.Knox, Susan J.Ning, ShouchengPeehl, Donna M.Korn, RonStirn, MeaghanCarter, Corey A.Oronsky, ArnoldTaylor, Michael J.Fitch, William L.Cabrales, PedroKim, Michelle M.Burris, Howard A.Lao, Christopher D.Abrouk, Nacer E. D.Fanger, Gary R.Infante, Jeffrey R.
- [22] A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Shapiro, GeoffreySupko, Jeffrey G.Cho, Daniel C.Hilton, John FrederickHadfield, MatthewPruitt-Thompson, SalidaBordoli-Trachsela, EvelineZvereva, NelaWolanski, AndrewSato-DiLorenzo, AyaGotthardt, SusanFox, Edward A.Verselis, Sigitas JonasKumar, AshokHolden, Sylvia A.Ram, SiyaChafai-Fadela, KarimaHarding, KimberlyMenon, Krishna E.
- [23] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Papadopoulos, K. P.Mendelson, D. S.Tolcher, A. W.Patnaik, A.Burris, H. A.Rasco, D. W.Bendell, J. C.Gordon, M. S.Kato, G.Wong, H.Bomba, D.Lee, S.Gillenwater, H. H.Woo, T.Infante, J. R.
- [24] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Hollebecque, AntoineSoria, Jean-CharlesBahleda, RatislavLopez-Busto, NatividadJacquet-Bescond, AnneBurbridge, Mike F.Valerie, CattanPauly, JeanneHerranz, MariaAzaro, AnaliaDepil, StephaneRodon, Jordi
- [25] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harvey, R. DonaldFalchook, Gerald StevenNaqash, Abdul RafehKim, Joseph W.Dowlati, AfshinLe Bruchec, YvanCoudert, IsabelleErvin-Haynes, Annette L.Sommerhalder, David
- [26] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsJournal of Hematology & Oncology, 9Tianhong LiPatricia LoRussoMichael L. MaitlandSai-Hong Ignatius OuErkut BahceciHoward A. BallJung Wook ParkGeoffrey YuenAnthony Tolcher
- [27] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Ho, A. L.Bendell, J. C.Cleary, J. M.Schwartz, G. K.Burris, H. A.Oakes, P.Agbo, F.Barker, P. N.Senderowicz, A. M.Shapiro, G.
- [28] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsJOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9Li, TianhongLoRusso, PatriciaMaitland, Michael L.Ou, Sai-Hong IgnatiusBahceci, ErkutBall, Howard A.Park, Jung WookYuen, GeoffreyTolcher, Anthony
- [29] A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2011, 17 (19) : 6313 - 6321Tabernero, JosepDirix, LucSchoffski, PatrickCervantes, AndresAntonio Lopez-Martin, JoseCapdevila, Jaumevan Beijsterveldt, LudyPlatero, SusoHall, BrettYuan, ZhilongKnoblauch, RolandZhuang, Sen Hong
- [30] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Kristeleit, Rebecca SophieShapiro, GeoffreyLoRusso, PatriciaInfante, Jeffrey R.Flynn, MichaelPatel, Manish R.Tolaney, Sara M.Hilton, John FrederickCalvert, Alan HilaryGiordano, HeidiIsaacson, Jeffrey D.Borrow, JenniferAllen, Andrew R.Jaw-Tsai, Sarah S.Burris, Howard A.